Kezhen Fei
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Kezhen Fei has a total of 68 co-authors. Here are the top co-authors by number of shared publications:
- Adrian J. Fretland
10Repare Therapeutics, Cambridge, Massachusetts
18 shared publications - Anne Roulston
Repare Therapeutics, Saint-Laurent, Canada
18 shared publications - Benedito Arruda Carneiro
Legorreta Cancer Center, Brown University, Providence, RI 02912, USA
18 shared publications - Danielle Ulanet
Repare Therapeutics, Cambridge, Massachusetts
18 shared publications - Devalingam Mahalingam
Developmental Therapeutics, Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA
18 shared publications - Elisa Fontana
Sarah Cannon Research Institute UK, London, United Kingdom
18 shared publications
Latest Publications
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from Camonsertib, an ATRi, in Combination with Low-Dose Gemcitabine in Solid Tumors with DNA Damage Response Aberrations: Preclinical and Phase Ib Results
Kaplan-meier estimate for A, DOT and B, PFS in patients with and without reversions enrolled on LoF in BRCA1/2, RAD51p, or PALB2 in HRD associated tumor types (breast, prostate, pancreatic, ovarian) C) On-treatment BRCA1 reversion detected (RECIST and ctDNA cTF in Fig. 3D)
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from Camonsertib, an ATRi, in Combination with Low-Dose Gemcitabine in Solid Tumors with DNA Damage Response Aberrations: Preclinical and Phase Ib Results
Kaplan-meier estimate for A, DOT and B, PFS in patients with and without reversions enrolled on LoF in BRCA1/2, RAD51p, or PALB2 in HRD associated tumor types (breast, prostate, pancreatic, ovarian) C) On-treatment BRCA1 reversion detected (RECIST and ctDNA cTF in Fig. 3D)
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Camonsertib, an ATRi, in Combination with Low-Dose Gemcitabine in Solid Tumors with DNA Damage Response Aberrations: Preclinical and Phase Ib Results
Camonsertib concentration levels at 80 and 120 mg – cycle 1 day 1
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Camonsertib, an ATRi, in Combination with Low-Dose Gemcitabine in Solid Tumors with DNA Damage Response Aberrations: Preclinical and Phase Ib Results
Camonsertib concentration levels at 80 and 120 mg – cycle 1 day 1
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Camonsertib, an ATRi, in Combination with Low-Dose Gemcitabine in Solid Tumors with DNA Damage Response Aberrations: Preclinical and Phase Ib Results
Study schematic for TRESR, Module 4.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Camonsertib, an ATRi, in Combination with Low-Dose Gemcitabine in Solid Tumors with DNA Damage Response Aberrations: Preclinical and Phase Ib Results
Study schematic for TRESR, Module 4.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Camonsertib, an ATRi, in Combination with Low-Dose Gemcitabine in Solid Tumors with DNA Damage Response Aberrations: Preclinical and Phase Ib Results
Institutional Review Boards of participating institutions
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Camonsertib, an ATRi, in Combination with Low-Dose Gemcitabine in Solid Tumors with DNA Damage Response Aberrations: Preclinical and Phase Ib Results
Institutional Review Boards of participating institutions
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S5 from Camonsertib, an ATRi, in Combination with Low-Dose Gemcitabine in Solid Tumors with DNA Damage Response Aberrations: Preclinical and Phase Ib Results
Drug combination pharmacokinetic parameters
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S5 from Camonsertib, an ATRi, in Combination with Low-Dose Gemcitabine in Solid Tumors with DNA Damage Response Aberrations: Preclinical and Phase Ib Results
Drug combination pharmacokinetic parameters
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table 2 from Camonsertib, an ATRi, in Combination with Low-Dose Gemcitabine in Solid Tumors with DNA Damage Response Aberrations: Preclinical and Phase Ib Results
TRAEs by schedule and grade in >5% of the total study population.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable 2 from Camonsertib, an ATRi, in Combination with Low-Dose Gemcitabine in Solid Tumors with DNA Damage Response Aberrations: Preclinical and Phase Ib Results
TRAEs by schedule and grade in >5% of the total study population.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Camonsertib, an ATRi, in Combination with Low-Dose Gemcitabine in Solid Tumors with DNA Damage Response Aberrations: Preclinical and Phase Ib Results
Mice bearing SUM149PT (A and C) or Granta-519 (B) tumors were treated with camonsertib (3/4d, weekly) or gemcitabine (QW) as single agents and in combination at the doses indicated. A) Tumor growth is represented as mean ± SEM; n = 7 mice/group; TGI = tumor growth inhibition (%). B, C) Body weights are represented as mean change relative to Day 0 ± SEM. Statistical differences between groups were determined using an unpaired t-test with Welch’s correction. *P < .05; **P < .01 (GraphPad Prism v10.4).
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Camonsertib, an ATRi, in Combination with Low-Dose Gemcitabine in Solid Tumors with DNA Damage Response Aberrations: Preclinical and Phase Ib Results
Mice bearing SUM149PT (A and C) or Granta-519 (B) tumors were treated with camonsertib (3/4d, weekly) or gemcitabine (QW) as single agents and in combination at the doses indicated. A) Tumor growth is represented as mean ± SEM; n = 7 mice/group; TGI = tumor growth inhibition (%). B, C) Body weights are represented as mean change relative to Day 0 ± SEM. Statistical differences between groups were determined using an unpaired t-test with Welch’s correction. *P < .05; **P < .01 (GraphPad Prism v10.4).
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from Camonsertib, an ATRi, in Combination with Low-Dose Gemcitabine in Solid Tumors with DNA Damage Response Aberrations: Preclinical and Phase Ib Results
TRAEs leading to dose reductions and/or interruptions
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from Camonsertib, an ATRi, in Combination with Low-Dose Gemcitabine in Solid Tumors with DNA Damage Response Aberrations: Preclinical and Phase Ib Results
TRAEs leading to dose reductions and/or interruptions
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Camonsertib, an ATRi, in Combination with Low-Dose Gemcitabine in Solid Tumors with DNA Damage Response Aberrations: Preclinical and Phase Ib Results
Treatment-emergent DLT adverse events
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from Camonsertib, an ATRi, in Combination with Low-Dose Gemcitabine in Solid Tumors with DNA Damage Response Aberrations: Preclinical and Phase Ib Results
Treatment-emergent DLT adverse events
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Camonsertib, an ATRi, in Combination with Low-Dose Gemcitabine in Solid Tumors with DNA Damage Response Aberrations: Preclinical and Phase Ib Results
Study representativeness table
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Camonsertib, an ATRi, in Combination with Low-Dose Gemcitabine in Solid Tumors with DNA Damage Response Aberrations: Preclinical and Phase Ib Results
Study representativeness table